升白欣对癌症化疗或放疗后白细胞减少症的疗效

Clinical Effect of Shengbaixin in the Treatment of Leukopenia after Chemotherapy or Radiotherapy of Cancer

为了观察升白欣对癌症患者化疗、放疗所致的白细胞减少症的疗效，作者于１９９６年７月至８月，将化疗、放疗所致白细胞减少的６８例癌症患者，随机分成升白欣治疗组（３５例）和一般升白细胞药的对照组（３３例）。结果表明，升白欣的升白细胞有效率６０．０％，明显高于对照组的２１．２％（Ｐ＜０．０１），治疗前白细胞中位值为２．６７×１０９／Ｌ±０．７９×１０９／Ｌ，治疗后升高为４．２５×１０９／Ｌ±２．２９××１０９／Ｌ。升白欣的副反应主要为发热（３４．８％）、注射部位疼痛（６５．７％）。作者认为，升白欣治疗化疗、放疗后所致白细胞减少症是有效的，有临床应用价值。

In order to observe the effect of Shengbaixin in the treatment of leukocytopenia induced by chemotherapy or radiotherapy of cancer, 68 cases of patients with leukocytopenia after chemotherapy and radiotherapy of cancer were randomly divided into two groups from July to August 1996. One group including 35 cases were treated by Shengbaixin (Group I),the other group including 33 cases as control by ordinary promoting leukocytogenesis drug (Group 2). The resutts showed that the effective rate of Group 1 was 60.0%, it was remarkably higher than that of Group 2 (21.2%)( P <0.01). The median leukocyte count of patients in Group 1 before treatment was 2.67×10 9/L±0.79×10 9/L, while it was elevated to 4.25×10 9/L±2.29×10 9/L, after treatment. The main side reactions of Shengbaixin are fever (34.8%) and pain in the site of injection (65.7%). The authore suggest that Shengbaixin is effective for leukocytopenina induced by chemotherapy or radiotherapy of cancer and worthy to be used in the clinical practice.